Missing one dose likely wont derail your progress, but frequently interrupting your oral semaglutide dose schedule can reduce long-term effectiveness
4 The FDA approved the Wegovy pill for weight loss on December 22, 2025 and its expected to be available to patients in early January 2026
While the beneficial effects of low IGF-1 action on aging seems well supported by data in model systems 6,7 and unique human populations 13,16 , a broader examination of the literature suggests that a more nuanced, complex, and controversial relationship exists between IGF-1, aging, and disease, which is indicative of the pleiotropic actions attributed to IGF-1 in cells and tissues 12,19
Zepbound is indicated for overweight adults who have at least one weight-related health condition, including hypertension, high cholesterol, or sleep apnea